الفهرس 
Prevalence & IncidenceOnly 14 pages are availabe for public view
 |  | from | 94 |  |  |
| | | from | 94 | | |
Abstract
The most common type of endocrine cancer is thyroid cancer. Cancer of the thyroid is the seventh most common type of cancer in women. In 2020, it is expected that 586,202 people around the world will be diagnosed with thyroid cancer. Differentiated thyroid carcinoma (DTC) is found in more than 90% of patients. Surgery is still the standard treatment for all patients with DTC, followed by radioiodine therapy (if needed) and thyroid hormone suppression therapy. Low-risk thyroid cancers are those that are not likely to come back or cause illness or death. After surgery, radioactive remnant ablation (RRA) is used to get rid of any remaining ”normal” thyroid tissue. In 2015, the American Thyroid Association (ATA) suggested that low dose RAI (30–50 mci) be used to permanently destroy low-risk DTC. So, the goal of this study was to find out how patients with low risk differentiated thyroid cancer (LRDTC) responded to low activity radioiodine ablation using the ATA dynamic risk assessment system. Between January 2013 and July 2019, a total of 35 patients diagnosed with low-risk differentiated thyroid carcinoma who sought treatment at the Mansoura clinical oncology and nuclear medicine department were analysed for this research.